OCR invests in the government’s research program (FUI° in collaboration with Ecrins Therapeutics, a pioneering french company in biotech’s field.

This collaboration applies the biological, genetic and pharmaceutical expertise in veterinary medicine to aid in the development of the drug ET-D5, which is used in the treatment of sarcomas in humans and pets.
Researchers hope this pre-clinical study will allow both human and pets access to clinical trials studying treatment for sarcoma.